Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Healthcare Biotechnology
Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Liminal BioSciences Inc.
Bullboard Posts
User Avatar Image
(3)
•••
Post by Felcoon Apr 02, 2015 12:38pm
210 Views
Post# 23591993

Cannacord research report

Cannacord research report

Canadian Equity Research

1 April 2015

BUY

unchanged

PRICE TARGET

unchanged

Price (1-Apr) Ticker

C$3.00

C$2.57 PLI-TSX

52-Week Range (C$):
Avg Daily Vol (000s) : Market Cap (C$M): Shares Out., FD (M) :
Total Return to Target (%) : Net Debt (Cash) (C$M): Long-Term Debt (C$):

0.85 - 2.87 1,371.7 1,407 547.6 16.7 (3.9) 23.2

FYE Dec

Sales (C$M)

Previous

R&D (C$M) SG&A (C$M) EBITDA (C$M) Previous

Net Income (C$M)

Previous

EPS (C$)

Previous

3 2.5 2 1.5 1 0.5

PLI Source: FactSet

2013A

2014A

(17.4) 2.6↑ (26.0)↓ (7.5)↓

(17.4) (7.3) (15.0) 2.0

(0.03) 0.00↑ (0.04)↓ (0.01)↓

68.4↓ 75.3 34.3 11.2 (30.0)↓ (21.2)↓ (2.2)↓ (8.7) (20.0) (10.4) 7.1

20.6

23.0↓ 25.6 35.2 12.9

49.1↓ 54.2 40.1 11.1

20.6

2015E

2016E

18.6 8.6 (8.7)

(0.03) (0.02)

(0.03) NA


Bullboard Posts
Dealroom for high-potential pre-IPO opportunities